Nicholas Investment Partners LP Invests $6.65 Million in IDEAYA Biosciences, Inc. $IDYA

Nicholas Investment Partners LP acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 192,413 shares of the company’s stock, valued at approximately $6,652,000. Nicholas Investment Partners LP owned about 0.22% of IDEAYA Biosciences as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Farther Finance Advisors LLC lifted its position in shares of IDEAYA Biosciences by 171.1% during the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after buying an additional 580 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of IDEAYA Biosciences during the 3rd quarter worth approximately $38,000. ANTIPODES PARTNERS Ltd lifted its position in shares of IDEAYA Biosciences by 49.4% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after buying an additional 380 shares in the last quarter. Abich Financial Wealth Management LLC bought a new position in shares of IDEAYA Biosciences during the 3rd quarter worth approximately $58,000. Finally, Global Retirement Partners LLC bought a new position in shares of IDEAYA Biosciences during the 4th quarter worth approximately $61,000. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Price Performance

IDYA opened at $28.98 on Friday. The company has a fifty day moving average price of $29.89 and a 200-day moving average price of $32.49. The firm has a market capitalization of $2.55 billion, a P/E ratio of -18.11 and a beta of -0.05. IDEAYA Biosciences, Inc. has a one year low of $20.50 and a one year high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The firm had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.04 million. During the same period in the prior year, the company earned ($0.82) earnings per share. The business’s revenue was down 39.4% compared to the same quarter last year. On average, analysts expect that IDEAYA Biosciences, Inc. will post -4.27 earnings per share for the current year.

Analyst Ratings Changes

IDYA has been the subject of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Friday, May 22nd. Wedbush restated an “outperform” rating and set a $58.00 price target on shares of IDEAYA Biosciences in a research note on Friday. Wall Street Zen upgraded shares of IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. Guggenheim raised their price target on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. Finally, Truist Financial set a $65.00 price target on shares of IDEAYA Biosciences in a research note on Monday, April 13th. Fifteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.69.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.